222 related articles for article (PubMed ID: 17602229)
1. TNF inhibitors for ankylosing spondylitis in the real world.
McVeigh CM; Bell AL; Cairns AP
Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
[No Abstract] [Full Text] [Related]
2. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
3. Switching anti-TNF therapy in ankylosing spondylitis.
Pradeep DJ; Keat AC; Gaffney K; Brooksby A; Leeder J; Harris C
Rheumatology (Oxford); 2008 Nov; 47(11):1726-7. PubMed ID: 18782856
[No Abstract] [Full Text] [Related]
4. Predicting outcome in ankylosing spondylitis.
Pradeep DJ; Keat A; Gaffney K
Rheumatology (Oxford); 2008 Jul; 47(7):942-5. PubMed ID: 18492709
[No Abstract] [Full Text] [Related]
5. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Sieper J; Rudwaleit M
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
[TBL] [Abstract][Full Text] [Related]
6. The impact of the NICE appraisal consultation document on anti-TNF therapy for ankylosing spondylitis.
Smith N; Gadsby K; Butt S; Deighton C
Rheumatology (Oxford); 2007 Jun; 46(6):1044-5. PubMed ID: 17401132
[No Abstract] [Full Text] [Related]
7. [Spondyloarthritis].
Sieper J
Z Rheumatol; 2004 Jun; 63(3):185-6. PubMed ID: 15224220
[No Abstract] [Full Text] [Related]
8. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
9. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
10. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
Temel M; Atagündüz P; Direskeneli H
Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
[No Abstract] [Full Text] [Related]
11. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
[No Abstract] [Full Text] [Related]
12. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
Hermann J; Müller T; Yazdani-Biuki B; Aringer M; Herold M; Ebner W; Ofner P; Graninger W
Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
[No Abstract] [Full Text] [Related]
13. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
14. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
15. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
Jois RN; Gaffney K; Keat A
Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
[No Abstract] [Full Text] [Related]
16. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Bijlsma JW; Dougados M; Emery P; Keystone EC; Klareskog L; Mease PJ
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv2-14. PubMed ID: 16239380
[No Abstract] [Full Text] [Related]
17. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
[No Abstract] [Full Text] [Related]
18. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
Song IH; Rudwaleit M; Listing J; Sieper J
Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
[TBL] [Abstract][Full Text] [Related]
19. Physical therapy in anti-TNF treated patients with ankylosing spondylitis.
Dubey SG; Leeder J; Gaffney K
Rheumatology (Oxford); 2008 Jul; 47(7):1100-1. PubMed ID: 18495822
[No Abstract] [Full Text] [Related]
20. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
Song IH; Maksymowych WP
Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
